56 research outputs found
Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse
Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: Experience by the Italian Association of Pediatric Hematology and Oncology
The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol
On the basis of the results of previous national and international trials and studies, the
Renal Tumour Study Group of the International Society of Paediatric Oncology (SIOPâRTSG) has
developed a new study protocol for paediatric renal tumours: the UMBRELLA SIOPâRTSG 2016
protocol (the UMBRELLA protocol). Currently, the overall outcomes of patients with Wilms
tumour are excellent, but subgroups with poor prognosis and increased relapse rates still exist.
The identification of these subgroups is of utmost importance to improve treatment stratification,
which might lead to reduction of the direct and late effects of chemotherapy. The UMBRELLA
protocol aims to validate new prognostic factors, such as blastemal tumour volume and molecular
markers, to further improve outcome. To achieve this aim, large, international, high-quality
databases are needed, which dictate optimization and international harmonization of specimen
handling and comprehensive sampling of biological material, refine definitions and improve
logistics for expert review. To promote broad implementation of the UMBRELLA protocol, the
updated SIOPâRTSG pathology and molecular biology protocol for Wilms tumours has been
outlined, which is a consensus from the SIOPâRTSG pathology panel
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK)
: Clear cell sarcoma of the kidney (CCSK) is a rare pediatric renal tumor with a worse prognosis than Wilms' tumor. Although recently, BCOR internal tandem duplication (ITD) has been found as a driver mutation in more than 80% of cases, a deep molecular characterization of this tumor is still lacking, as well as its correlation with the clinical course. The aim of this study was to investigate the differential molecular signature between metastatic and localized BCOR-ITD-positive CCSK at diagnosis. Whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) were performed on six localized and three metastatic BCOR-ITD-positive CCSKs, confirming that this tumor carries a low mutational burden. No significant recurrences of somatic or germline mutations other than BCOR-ITD were identified among the evaluated samples. Supervised analysis of gene expression data showed enrichment of hundreds of genes, with a significant overrepresentation of the MAPK signaling pathway in metastatic cases (p < 0.0001). Within the molecular signature of metastatic CCSK, five genes were highly and significantly over-expressed: FGF3, VEGFA, SPP1, ADM, and JUND. The role of FGF3 in the acquisition of a more aggressive phenotype was investigated in a cell model system obtained by introducing the ITD into the last exon of BCOR by Crispr/Cas9 gene editing of the HEK-293 cell line. Treatment with FGF3 of BCOR-ITD HEK-293 cell line induced a significant increase in cell migration versus both untreated and scramble cell clone. The identification of over-expressed genes in metastatic CCSKs, with a particular focus on FGF3, could offer new prognostic and therapeutic targets in more aggressive cases
Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature
In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%.
However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors
currently used for risk stratification (advanced stage, high risk histology, and combined loss of
heterozygosity at 1p and 16q in chemotherapy-naĂŻve WTs) are present in only one third of these cases,
and the significance of these factors is prone to change with advancing knowledge and improved
treatment regimens. Therefore, we present a comprehensive, updated overview of the published
prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil
the importance of further investigating the significance of biological markers for WT recurrence in
international collaborations
Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse
n/
Is Wilms Tumor a Candidate Neoplasia for Treatment with WNT/ÎČ-Catenin Pathway Modulators?-A Report from the Renal Tumors Biology-Driven Drug Development Workshop
The European Network for Cancer Research in Children and Adolescents (ENCCA) consortium organized a workshop in Rome, in June 2012, on âRenal Tumor Biology Driven Drug Developmentâ to discuss the current knowledge in pediatric renal cancers and to recommend directions for further research. Wilms tumor (WT) is the most common renal tumor of childhood and represents a success of pediatric oncology, with cure rates of over 85% of cases. However, a substantial minority (~25%) responds poorly to current therapies and requires âhigh riskâ treatment or relapse. Moreover, the successfully treated majority are vulnerable to the late effects of treatment, with nearly one quarter reporting severe chronic health conditions by 25 years of follow up. Main purposes of this meeting were: to advance our understanding on the molecular drivers in WT, their heterogeneity and interdependencies; to provide updates on the clinic-pathologic associations with biomarkers; to identify eligible populations for targeted drugs; and to model opportunities to use preclinical model systems and prioritize targeted agents for early phase clinical trials. At least three different pathways are involved in WT; this review represents the outcome of the workshop discussion on the WNT/ÎČ-catenin pathway in Wilms tumorigenesis
Distinct Methylation Changes at the IGF2-H19 Locus in Congenital Growth Disorders and Cancer
Background: Differentially methylated regions (DMRs) are associated with many imprinted genes. In mice methylation at a DMR upstream of the H19 gene known as the Imprint Control region (IC1) is acquired in the male germline and influences the methylation status of DMRs 100 kb away in the adjacent Insulin-like growth factor 2 (Igf2) gene through long-range interactions. In humans, germline-derived or post-zygotically acquired imprinting defects at IC1 are associated with aberrant activation or repression of IGF2, resulting in the congenital growth disorders Beckwith-Wiedemann (BWS) and Silver-Russell (SRS) syndromes, respectively. In Wilms tumour and colorectal cancer, biallelic expression of IGF2 has been observed in association with loss of methylation at a DMR in IGF2. This DMR, known as DMR0, has been shown to be methylated on the silent maternal IGF2 allele presumably with a role in repression. The effect of IGF2 DMR0 methylation changes in the aetiology of BWS or SRS is unknown. Methodology/Principal Findings: We analysed the methylation status of the DMR0 in BWS, SRS and Wilms tumour patients by conventional bisulphite sequencing and pyrosequencing. We show here that, contrary to previous reports, the IGF2 DMR0 is actually methylated on the active paternal allele in peripheral blood and kidney. This is similar to the IC
Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020
We describe clinical characteristics, treatments and outcomes of 44 Caucasian patients with coronavirus disease (COVID-19) at a single hospital in Pavia, Italy, from 21\u201328 February 2020, at the beginning of the outbreak in Europe. Seventeen patients developed severe disease, two died. After a median of 6 days, 14 patients were discharged from hospital. Predictors of lower odds of discharge were age>65 years, antiviral treatment and for severe disease, lactate dehydrogenase >300 mg/dL
- âŠ